Acasti Pharma Inc. to Showcase at the Cambridge Healthtech Institute and the BioPharmaceutical Strategy Series
April 14 2010 - 8:30AM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) announces that Acasti Pharma Inc.
("Acasti") is a proud sponsor and presenter at the 7th Annual
Alliance Management congress and the 2nd Annual Combination Drug
Therapies Conference, both organized by the Cambridge Healthtech
Institute (CHI) and the BioPharmaceutical Strategy Series to be
held April 13-14 in Philadelphia, PA. Acasti will present its
unique positioning in the field of Cardiometabolic disorders and
its action plan for successful collaboration with worldwide
pharmaceutical industry leaders and its strategy for
implementation.
Acasti believes that the latest results obtained and publicly
presented at scientific meetings by Acasti position the company to
increase its share of the cardiovascular pharmaceutical market.
Acasti is working towards generating short-term revenues while
pursuing the pharmaceutical development of its prescription drug
candidate (CaPre™). CaPre™ was shown to be effective in
beneficially modulating mixed lipid profiles in various healthy and
diseased rat and mouse models, which exhibit high cholesterol,
harboring obesity and diabetes conditions, by significantly
reducing triglycerides (60%) and bad cholesterol - LDL (28%) while
simultaneously increasing good cholesterol - HDL (25%).
The presentation will highlight that nutraceuticals, medical
foods, over-the-counter and prescribed drugs are no longer being
developed in silos, thus revealing new horizons. Acasti will
give an overview and perspectives for combination products in all
four areas, encompassing regulatory challenges and new business
opportunities. In Acasti's view, the industry should be determined
to develop and commercialize innovative approaches that combine the
best options to benefit patients.
"It is quite a unique opportunity for Acasti to introduce itself
and exchange views on its corporate strategy in seeking alliances
for its new product lines, while providing opportunities for in/out
licensing agreements," said Dr. Tina Sampalis, President of Acasti
Pharma Inc. "This is the first time that Acasti goes public in that
sort of forum while showcasing its platform and products to the
pharmaceutical industry. It is the beginning of a long-term
relationship that we want to establish with international and
strategic industrial partners who are seeking the next best product
to manage the complexity of mixed dyslipidemia associated with the
ever-increasing problems of obesity and diabetes," she added.
About Neptune Technologies & Bioressources Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or
implied by such forward-looking statements. In addition to
statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labeled with the
terms "believes," "belief," "expects," "intends," "anticipates,"
"will," or "plans" to be uncertain and forward-looking. The
forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the
Securities and Exchange Commission and the Canadian
securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Acasti Pharma Inc.
Dr. Tina Sampalis, President
+1 450.686.4555
t.sampalis@acastipharma.com
www.acastipharma.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024